|Articles|December 8, 2014

Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

Author(s)Agnes Shanley

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.

 

 

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content